GSK plc (NYSE:GSK) Given Consensus Recommendation of “Hold” by Analysts

GSK plc (NYSE:GSK) has earned a consensus rating of “Hold” from the five ratings firms that are currently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and three have issued a buy recommendation on the company.

Several equities research analysts have weighed in on GSK shares. Guggenheim raised shares of GSK from a “neutral” rating to a “buy” rating in a research note on Monday, March 4th. Citigroup raised GSK from a “neutral” rating to a “buy” rating in a research report on Tuesday, February 13th.

GSK Stock Down 0.1 %

Shares of NYSE:GSK opened at $45.12 on Monday. GSK has a 1 year low of $33.33 and a 1 year high of $45.92. The company has a debt-to-equity ratio of 1.15, a current ratio of 0.87 and a quick ratio of 0.58. The business’s 50-day moving average is $42.53 and its 200-day moving average is $40.20. The company has a market capitalization of $93.51 billion, a price-to-earnings ratio of 16.35, a P/E/G ratio of 1.36 and a beta of 0.65.

GSK (NYSE:GSK) last issued its quarterly earnings results on Wednesday, May 1st. The pharmaceutical company reported $1.09 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.94 by $0.15. The firm had revenue of $9.34 billion for the quarter, compared to analyst estimates of $8.98 billion. GSK had a return on equity of 51.54% and a net margin of 14.62%. Equities research analysts predict that GSK will post 4.12 earnings per share for the current year.

GSK Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, July 11th. Shareholders of record on Friday, May 17th will be paid a $0.3762 dividend. This represents a $1.50 dividend on an annualized basis and a dividend yield of 3.34%. This is a positive change from GSK’s previous quarterly dividend of $0.36. The ex-dividend date is Thursday, May 16th. GSK’s dividend payout ratio (DPR) is 53.26%.

Institutional Investors Weigh In On GSK

Several hedge funds and other institutional investors have recently made changes to their positions in GSK. Versant Capital Management Inc raised its stake in shares of GSK by 2,816.7% in the fourth quarter. Versant Capital Management Inc now owns 700 shares of the pharmaceutical company’s stock worth $26,000 after purchasing an additional 676 shares during the last quarter. Register Financial Advisors LLC purchased a new stake in GSK in the 1st quarter valued at $31,000. BKM Wealth Management LLC bought a new position in GSK during the 4th quarter valued at $32,000. Richardson Financial Services Inc. purchased a new position in GSK during the 4th quarter worth $40,000. Finally, Jones Financial Companies Lllp grew its stake in shares of GSK by 62.2% in the 3rd quarter. Jones Financial Companies Lllp now owns 1,327 shares of the pharmaceutical company’s stock worth $48,000 after acquiring an additional 509 shares in the last quarter. 15.74% of the stock is owned by institutional investors.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.